Downregulation of MUC1 expression and its recognition by CD8 + T cells on the surface of malignant pleural mesothelioma cells treated with HDACi

European Journal of Immunology

Volumn 42, Issue 3, 2012, Pages 783-789

  Roulois, David ^a,b   Blanquart, Christophe ^a,b   Panterne, Clarisse ^a,b   Gueugnon, Fabien ^a   Grégoire, Marc ^a,b   Fonteneau, Jean François ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

CD8 + T cells; HDACi; Mesothelioma; Mucin1; VPA

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE DEACETYLASE INHIBITOR; HLA ANTIGEN CLASS 1; MUCIN 1; NY ESO 1 ANTIGEN; TUMOR ANTIGEN; VALPROIC ACID;

ARTICLE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DOWN REGULATION; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURAL MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION;

ANTIGENS, NEOPLASM; AZACITIDINE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DOWN-REGULATION; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HUMANS; KINETICS; MEMBRANE PROTEINS; MESOTHELIOMA; MUCIN-1; REAL-TIME POLYMERASE CHAIN REACTION; RNA; STATISTICS, NONPARAMETRIC; VALPROIC ACID;

EID: 84859494423     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201141800     Document Type: Article

References (30)

1. Kazan-Allen, L., Asbestos and mesothelioma: worldwide trends. Lung Cancer 2005. 49: S3-S8.
2. Robinson, B. W., Musk, A. W. and Lake, R. A., Malignant mesothelioma. Lancet 2005. 366: 397-408.
3. Scherpereel, A., Astoul, P., Baas, P., Berghmans, T., Clayson, H., de Vuyst, P., Dienemann, H. et al., Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur. Respir. J. 2010. 35: 479-495.
4. Krug, L. M., Curley, T., Schwartz, L., Richardson, S., Marks, P., Chiao, J. and Kelly, W. K., Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin. Lung Cancer 2006. 7: 257-261.
5. Kuendgen, A. and Gattermann, N., Valproic acid for the treatment of myeloid malignancies. Cancer 2007. 110: 943-954.
6. Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R. and Pazdur, R., FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007. 12: 1247-1252.
7. Paik, P. K. and Krug, L. M., Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J. Thorac. Oncol. 2010. 5: 275-279.
8. Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A. et al., Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin. Cancer Res. 2006. 12: 5777-5785.
9. Vandermeers, F., Hubert, P., Delvenne, P., Mascaux, C., Grigoriu, B., Burny, A., Scherpereel, A. and Willems, L., Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin. Cancer Res. 2009. 15: 2818-2828.
10. Plimack, E. R., Kantarjian, H. M. and Issa, J. P., Decitabine and its role in the treatment of hematopoietic malignancies. Leuk. Lymphoma 2007. 48: 1472-1481.
11. Lane, A. A. and Chabner, B. A., Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009. 27: 5459-5468.
12. Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B. et al., Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005. 23: 3923-3931.
13. Blanquart, C., François, M., Charrier, C., Bertrand, P. and Gregoire, M., Pharmacological characterization of histone deacetylase and tumor cell growth inhibition properties of new benzafuranone compounds. Curr. Cancer Drug Target 2011. 11: 919-928.
14. Sigalotti, L., Coral, S., Altomonte, M., Natali, L., Gaudino, G., Cacciotti, P., Libener, R. et al., Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br. J. Cancer. 2002. 86: 979-982.
15. Weiser, T. S., Guo, Z. S., Ohnmacht, G. A., Parkhurst, M. L., Tong-On, P., Marincola, F. M., Fischette, M. R. et al., Sequential 5-aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J. Immunother. 2001. 24: 151-161.
16. Leclercq, S., Gueugnon, F., Boutin, B., Guillot, F., Blanquart, C., Rogel, A., Padieu, M. et al., 5-Aza-2′-deoxycytidine/valproate combination induces CTL response against mesothelioma. Eur. Respir. J. 2011. 38: 1105-1116.
17. Guillot, F., Boutin, B., Blanquart, C., Fonteneau, J. F., Robard, M., Grégoire, M. and Pouliquen, D., Immunization against a murine model of aggressive mesothelioma. Vaccine 2011. 29: 5534-5543.
18. Beatson, R. E., Taylor-Papadimitriou, J. and Burchell, J. M., MUC1 immunotherapy. Immunotherapy 2010. 2: 305-327.
19. Gao, J., McConnell, M. J., Yu, B., Li, J., Balko, J. M., Black, E. P., Johnson, J. O. et al., MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int. J. Oncol. 2009. 35: 337-345.
20. Kufe, D. W., Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 2009. 9: 874-885.
21. Li, Y., Liu, D., Chen, D., Kharbanda, S. and Kufe, D., Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 2003. 22: 6107-6110.
22. + T lymphocyte. Eur. Respir. J. 2011. 38: 1117-1126.
23. Brossart, P., Heinrich, K. S., Stuhler, G., Behnke, L., Reichardt, V. L., Stevanovic, S., Muhm, A. et al., Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999. 93: 4309-4317.
24. Akers, S. N., Odunsi, K. and Karpf, A. R., Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol. 2010. 6: 717-732.
25. Dubovsky, J. A., Wang, D., Powers, J. J., Berchmans, E., Smith, M. A., Wright, K. L., Sotomayor, E. M. and Pinilla-Ibarz, J. A., Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leuk. Res. 2011. 35: 394-404.
26. + T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010. 116: 1908-1918.
27. Guo, Z. S., Hong, J. A., Irvine, K. R., Chen, G. A., Spiess, P. J., Liu, Y., Zeng, G. et al., De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 2006. 66: 1105-1113.
28. Gueugnon, F., Leclercq, S., Blanquart, C., Sagan, C., Cellerin, L., Padieu, M., Perigaud, C. et al., Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am. J. Pathol. 2011. 178: 1033-1042.
29. + T-cell clones using peptide pulsed mature dendritic cells. J. Immunol. Methods 2001. 258: 111-126.
30. Espevik, T. and Nissen-Meyer, J., A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods 1986. 95: 99-105.